Eupraxia Pharmaceuticals Financials - Benzinga

Eupraxia Pharmaceuticals Inc

EPRXNASDAQ

Trade with Public

Trade with Public

$6.67

-0.69-9.31%

At close: Aug 28, 5:00 PM EST

$7.49

0.8212.21%

After Hours: Aug 27, 7:26 AM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Compare Stock Report

Eupraxia Pharmaceuticals Financials

Eupraxia Pharmaceuticals (EPRX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Eupraxia Pharmaceuticals Q2 EPS $(0.23), Inline

Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.23) per share which met the analyst consensus estimate. This is a 11.54 percent increase over losses of $(0.26) per share from the same period last

Benzinga Newsdesk

PRO
Eupraxia Pharmaceuticals Q1 EPS $(0.23) Misses $(0.22) Estimate

Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.22) by 4.55 percent. This is a 9.52 percent decrease over losses of $(0.21) per

Benzinga Newsdesk

PRO
Eupraxia Pharmaceuticals Q4 EPS $(0.37) Misses $(0.16) Estimate

Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.16) by 131.25 percent. This is a 68.18 percent decrease over losses of $(0.22) per

Benzinga Newsdesk

PRO
Eupraxia Pharmaceuticals Q3 EPS $(0.19) Beats $(0.21) Estimate

Benzinga Newsdesk

PRO
Eupraxia Pharmaceuticals Q2 EPS $(0.26) Misses $(0.19) Estimate

Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.19) by 36.84 percent. This is a 52.94 percent decrease over losses of $(0.17) per

Benzinga Newsdesk

PRO
Eupraxia Pharmaceuticals Q1 EPS $(0.21) Beats $(0.23) Estimate

Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.23) by 8.7 percent. This is unchanged from the same period last year.

Benzinga Newsdesk